Your browser doesn't support javascript.
Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot.
Mak, Baldwin C; Addeman, Bryan T; Chen, Jia; Papp, Kim A; Gooderham, Melinda J; Guenther, Lyn C; Liu, Yi; Broedl, Uli C; Logger, Marianne E.
  • Mak BC; Department of Clinical Operations, Boehringer Ingelheim Canada Ltd./Ltée, Burlington, ON, Canada.
  • Addeman BT; International Business Machines (IBM), Markham, ON, Canada.
  • Chen J; International Business Machines (IBM), Yorktown Heights, NY, USA.
  • Papp KA; K. Papp Clinical Research and Probity Medical Research Inc., Waterloo, ON, Canada.
  • Gooderham MJ; SKiN Centre for Dermatology, Peterborough, ON, Canada.
  • Guenther LC; The Guenther Dermatology Research Centre, London, ON, Canada.
  • Liu Y; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
  • Broedl UC; Global Clinical Development & Operations, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
  • Logger ME; Department of Clinical Operations, Boehringer Ingelheim Canada Ltd./Ltée, Burlington, ON, Canada.
Blockchain Healthc Today ; 42021.
Article in English | MEDLINE | ID: covidwho-2026452
ABSTRACT

Objective:

Despite the implementation of quality assurance procedures, current clinical trial management processes are time-consuming, costly, and often susceptible to error. This can result in limited trust, transparency, and process inefficiencies, without true patient empowerment. The objective of this study was to determine whether blockchain technology could enforce trust, transparency, and patient empowerment in the clinical trial data management process, while reducing trial cost.

Design:

In this proof of concept pilot, we deployed a Hyperledger Fabric-based blockchain system in an active clinical trial setting to assess the impact of blockchain technology on mean monitoring visit time and cost, non-compliances, and user experience. Using a parallel study design, we compared differences between blockchain technology and standard methodology.

Results:

A total of 12 trial participants, seven study coordinators and three clinical research associates across five sites participated in the pilot. Blockchain technology significantly reduces total mean monitoring visit time and cost versus standard trial management (475 to 7 min; P = 0.001; €722 to €10; P = 0.001 per participant/visit, respectively), while enhancing patient trust, transparency, and empowerment in 91, 82 and 63% of the patients, respectively. No difference in non-compliances as a marker of trial quality was detected.

Conclusion:

Blockchain technology holds promise to improve patient-centricity and to reduce trial cost compared to conventional clinical trial management. The ability of this technology to improve trial quality warrants further investigation.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Language: English Year: 2021 Document Type: Article Affiliation country: Bhty.v4.182

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Language: English Year: 2021 Document Type: Article Affiliation country: Bhty.v4.182